Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; Department of Neurology, Qingdao Municipal Hospital, College of Medicine and Pharmaceutics, Ocean University of China, Qingdao, China.
Ageing Res Rev. 2022 Sep;80:101655. doi: 10.1016/j.arr.2022.101655. Epub 2022 Jun 2.
Alzheimer's disease (AD) places a heavy burden on the global economy. There is no effective disease-modifying treatment available at present. Since the advent of induced pluripotent stem cells (iPSCs) reprogrammed from human somatic cells, new approaches using iPSC-derived products provided novel insights into AD pathogenesis and drug candidates for AD treatment. Multiple recent studies using animal models have increased the possibility of reducing pathology and improving cognitive function through cell replacement therapies. In this review, we summarized the advantages, limitations, and future directions of cell replacement therapy, discussed the safety and ethical concerns of this novel therapeutic approach and the possibility of translation to clinical practice.
阿尔茨海默病(AD)给全球经济带来了沉重负担。目前尚无有效的疾病修饰治疗方法。自从诱导多能干细胞(iPSC)从人类体细胞重编程问世以来,利用 iPSC 衍生产品的新方法为 AD 发病机制和 AD 治疗的药物候选物提供了新的见解。最近使用动物模型的多项研究增加了通过细胞替代疗法减少病理学和改善认知功能的可能性。在这篇综述中,我们总结了细胞替代疗法的优势、局限性和未来方向,讨论了这种新型治疗方法的安全性和伦理学问题及其转化为临床实践的可能性。